ArticleMedicine2026
Association between the Dietary Index for Gut Microbiota and all-cause mortality in coronary heart disease: A retrospective cohort analysis of NHANES (2005-2018).
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The Dietary Index for Gut Microbiota (DI-GM) is a novel metric assessing diet quality in relation to gut microbial composition. However, its association with all-cause mortality (ACM) in coronary heart disease (CHD) patients remains unexplored. This study aimed to evaluate the association between DI-GM and ACM among the CHD population. This retrospective cohort study utilized 2005-2018 National Health and Nutrition Examination Survey data. DI-GM scores were calculated based on 24-hour dietary recall data. The association between DI-GM and ACM in CHD patients was assessed using weighted Cox proportional hazards models and restricted cubic spline analyses. Subgroup analyses and interaction tests were performed to examine the robustness of the findings and potential effect modifiers. A total of 1537 CHD patients were included, representing 81,24,166 US adults. The overall ACM rate was 37.41%. Higher DI-GM scores were significantly associated with lower ACM risk. Compared with participants with scores of 0 to 3, those with scores ≥6 and 5 had significantly reduced ACM risk, with hazard ratios of 0.593 (95% confidence interval: 0.413-0.851; P = .005) and 0.649 (95% confidence interval: 0.432-0.975; P = .037), corresponding to 40.7% and 35.1% reductions in ACM risk. Restricted cubic spline analysis revealed a nonlinear inverse association between DI-GM and ACM. Subgroup analyses indicated that diabetes status may modify this association (P for interaction = .046). Higher DI-GM scores were nonlinearly and inversely associated with ACM among CHD patients. This association may be modified by diabetes status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.